ClinicalTrials.gg
CompletedNCT02000427Updated May 28, 2024Results posted

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

A Phase 2 interventional study of Blinatumomab in Relapsed/Refractory Philadelphia Positive B-precursor ALL, sponsored by Amgen. Completed at 22 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-28.

Primary conditionPrecursor Cell Lymphoblastic Leukemia-LymphomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's title name Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
39th of 61
45 · median 67
Started
2014
with 2 others
Phase 2
30 of 61
10 open now
Registered
6th of 61
by date
Lead sponsor
9 of 61
Amgen

Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 39th largest by enrollment, is one of 3 that started in 2014, is one of 30 in phase 2, and was the 6th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The primary objective is to evaluate the rate of complete remission/complete remission with partial hematological recovery (CRh*) in adults with relapsed/refractory Philadelphia chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who receive blinatumomab.

Read the detailed description

This is a single-arm Simon II stage design, multicenter study consisting of a screening period, an induction treatment period (2 cycles of blinatumomab), a consolidation treatment period (up to 3 additional cycles of blinatumomab for applicable participants), and a safety follow-up visit 30 days after treatment. Following the safety follow-up visit, participants will be followed for response duration and survival every 3 months for 18 months or death, whichever occurs first.

03

Conditions studied

  • Relapsed/Refractory Philadelphia Positive B-precursor ALL

Browse trials for

Keywords

  • Relapsed; Refractory; Philadelphia Positive; B-precursor; Acute Lymphoblastic Leukemia; ALL; Blinatumomab; Leukemia;
04

In context

Precursor Cell Lymphoblastic Leukemia-Lymphoma Reclassified

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

This study's enrollment of 45 is above the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Precursor Cell Lymphoblastic Leukemia-Lymphoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Ph+ B-precursor ALL, with any of the following:

    • to at least one second generation tyrosine kinase inhibitor (TKI) (dasatinib, nilotinib, bosutinib, ponatinib)
    • OR intolerant to second generation TKI and intolerant or refractory to imatinib mesylate
  • Greater than 5% blasts in bone marrow
  • (ECOG) performance status ≤ 2
  • Age ≥ 18 years of age, at the time of .
  • Subject has provided informed consent or subject's legally acceptable representative has provided informed consent when the subject has any kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent.

Exclusion criteria

Exclusion Criteria

  • History of other than ALL within 5 years prior to start of protocol-required therapy, except for adequately treated selected cancers without evidence of disease
  • History or presence of central nervous system (CNS) pathology as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis
  • Active ALL in the CNS or testes
  • Isolated extramedullary disease
  • Current disease or history of autoimmune disease with potential CNS involvement
  • hematopoietic stem cell transplantation (HSCT) within 12 weeks before blinatumomab treatment
  • Active acute or extensive chronic (GvHD) which included the administration of agents to prevent or treat GvHD within 2 weeks before blinatumomab treatment
  • immediately previous cancer chemotherapy, radiotherapy, or immunotherapy; and eligibility for allogeneic HSCT at the time of enrollment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Blinatumomab

    Participants will receive blinatumomab by continuous intravenous (CIVI) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieve a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab. The initial dose will be 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 for all subsequent cycles of treatment.

    Drug: Blinatumomab

Interventions

  • Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.

    Also known as: Blincyto®, AMG 103

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles

    Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts. Complete remission was defined as meeting all 3 of the following criteria: * less than or equal to 5% blasts in the bone marrow; * no evidence of disease * full recovery of peripheral blood counts: platelets \> 100,000/μl, and absolute neutrophil count (ANC) \> 1000/μl. Complete remission with partial hematological recovery (CRh\*) was defined as meeting all 3 of the following criteria: * less than or equal to 5% blasts in the bone marrow * no evidence of disease * partial recovery of peripheral blood counts: platelets \> 50,000/μl, and ANC \> 500/μl. Participants without a post-baseline disease assessment were considered non-responders.

    Time frame: Approximately 12 weeks, as of the data cut-off date of 20 May 2015

Secondary outcomes

  1. Percentage of Participants With Minimal Residual Disease (MRD) Remission During the First 2 Cycles of Treatment

    Bone marrow samples were evaluated for MRD remission by a central laboratory using bcr-abl fusion gene reverse transcription polymerase chain reaction (RT-PCR). An MRD response was defined as MRD \< 10\^-4 measured by PCR. Participants with no post-baseline MRD assessment were considered non-responders.

    Time frame: Approximately 12 weeks

  2. Duration of CR or CRh* Response

    Duration of response was measured for participants in remission (CR/CRh\*), and was measured from the time the participant first achieved remission until first documented relapse or death from disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of the last bone marrow assessment or the last survival follow-up visit to confirm remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their date of death.

    Time frame: Up to the data cut-off date of 20 May 2015; median observation time was 7.0 months

  3. Percentage of Participants With Complete Remission (CR) During the First Two Treatment Cycles

    Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts. Complete remission was defined as meeting all 3 of the following criteria: * less than or equal to 5% blasts in the bone marrow; * no evidence of disease; * full recovery of peripheral blood counts: platelets \> 100,000/μl, and absolute neutrophil count (ANC) \> 1000/μl. Participants without a post-baseline disease assessment were considered non-responders.

    Time frame: Approximately 12 weeks, as of the data cut-off date of 20 May 2015

  4. Percentage of Participants With Complete Remission With Partial Hematological Recovery (CRh*) During the First Two Treatment Cycles

    Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts. Complete remission with partial hematological recovery (CRh\*) was defined as meeting all 3 of the following criteria: * less than or equal to 5% blasts in the bone marrow; * no evidence of disease; * partial recovery of peripheral blood counts: platelets \> 50,000/μl, and ANC \> 500/μl. Participants without a post-baseline disease assessment were considered non-responders.

    Time frame: Approximately 12 weeks, as of the data cut-off date of 20 May 2015

  5. Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi) During the First Two Treatment Cycles

    Efficacy was evaluated via a central bone marrow aspiration and local peripheral blood counts. Complete remission was defined as meeting the following criteria: * less than or equal to 5% blasts in the bone marrow; * no evidence of disease; * full recovery of peripheral blood counts: platelets \> 100,000/μl, and absolute neutrophil count (ANC) \> 1000/μl. Complete remission with partial hematological recovery was defined as meeting the following criteria: * less than or equal to 5% blasts in the bone marrow; * no evidence of disease; * partial recovery of peripheral blood counts: platelets \> 50,000/μl, and ANC \> 500/μl. Complete remission with incomplete hematologic recovery was defined as meeting all of the following criteria: * less than or equal to 5% blasts in the bone marrow; * no evidence of disease; * incomplete recovery of peripheral blood counts: platelets \> 100,000/μl or ANC \> 1000/μl. Participants without a post-baseline disease assessment were considered non-responders.

    Time frame: Approximately 12 weeks, as of the data cut-off date of 20 May 2015

  6. Overall Survival

    Overall survival was assessed from the date the participant received the first infusion of blinatumomab until death from any cause or the date of the last follow-up. Participants still alive at the data cut-off date were censored on the last documented visit date or the date of the last contact when the patient was last known to have been alive.

    Time frame: From first dose of blinatumomab until the data cut-off date; median observation time was 8.8 months.

  7. Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission

    Participants who achieved remission (CR/CRh\*) during the first 2 cycles of treatment and received an allogeneic HSCT.

    Time frame: Up to the data cut-of date of 20 May 2015; Maximum duration on study was 14.5 months.

  8. 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant

    The analysis of 100-day mortality after allogeneic HSCT was assessed for participants who received an allogeneic HSCT while in remission (CR/CRh\*) after 2 cycles of blinatumomab treatment and did not receive any additional antileukemic treatment. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT. The 100-day mortality rate after allogeneic HSCT was defined as the percentage of participants having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive.

    Time frame: From the date of allogeneic HSCT until the data cut-off date of 20 May 2015; median observation time was 3.2 months.

  9. Number of Participants With Adverse Events

    Adverse events (AEs) were graded for severity according to the CTCAE version 4.0, where Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE. Treatment-related adverse events (TRAEs) were those assessed by the investigator as possibly related to blinatumomab based on response to the question: Is there a reasonable possibility that the event may have been caused by blinatumomab or other protocol-specified therapies/procedures?

    Time frame: From the first dose of blinatumomab until 30 days after the last dose, up to the cut-off date of 20 May 2015; the median duration of treatment was 53.8 days.

  10. Number of Participants Who Developed Anti-blinatumomab Antibodies

    Anti-blinatumomab binding antibodies were evaluated with a validated blinatumomab anti-drug antibody assay with the electrochemiluminescence detection technology.

    Time frame: Day 29 of each treatment period and 30 days after the last dose

  11. Steady State Concentration of Blinatumomab

    Time frame: Cycle 1, day 8, 6 to 8 hours after the dose step to 28 μg/day, and Cycle 2, day 1, 6 to 8 hours after blinatumomab infusion

08

Results

Posted Aug 9, 2017

Participant flow

This study was conducted at 19 centers in 4 European countries and the United States: 3 centers in France, 3 in Germany, 5 in Italy, 1 in the United Kingdom, and 7 in the United States. The first participant enrolled on 03 January 2014 and the last participant enrolled on 12 January 2015.

Participant flow — Overall Study
MilestoneBlinatumomab
Started45
Completed23
Not completed22
Withdrew: Death22

Outcome measures

PrimaryPercentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles

Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts. Complete remission was defined as meeting all 3 of the following criteria: * less than or equal to 5% blasts in the bone marrow; * no evidence of disease * full recovery of peripheral blood counts: platelets \> 100,000/μl, and absolute neutrophil count (ANC) \> 1000/μl. Complete remission with partial hematological recovery (CRh\*) was defined as meeting all 3 of the following criteria: * less than or equal to 5% blasts in the bone marrow * no evidence of disease * partial recovery of peripheral blood counts: platelets \> 50,000/μl, and ANC \> 500/μl. Participants without a post-baseline disease assessment were considered non-responders.

Time frame:
Approximately 12 weeks, as of the data cut-off date of 20 May 2015
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles
percentage of participantsBlinatumomab
Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles35.6 (21.9 to 51.2)
SecondaryPercentage of Participants With Minimal Residual Disease (MRD) Remission During the First 2 Cycles of Treatment

Bone marrow samples were evaluated for MRD remission by a central laboratory using bcr-abl fusion gene reverse transcription polymerase chain reaction (RT-PCR). An MRD response was defined as MRD \< 10\^-4 measured by PCR. Participants with no post-baseline MRD assessment were considered non-responders.

Time frame:
Approximately 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Minimal Residual Disease (MRD) Remission During the First 2 Cycles of Treatment
percentage of participantsBlinatumomab
Percentage of Participants With Minimal Residual Disease (MRD) Remission During the First 2 Cycles of Treatment40.0 (25.7 to 55.7)
SecondaryDuration of CR or CRh* Response

Duration of response was measured for participants in remission (CR/CRh\*), and was measured from the time the participant first achieved remission until first documented relapse or death from disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of the last bone marrow assessment or the last survival follow-up visit to confirm remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their date of death.

Time frame:
Up to the data cut-off date of 20 May 2015; median observation time was 7.0 months
Reported as:
Median · months
Duration of CR or CRh* Response
monthsBlinatumomab
Duration of CR or CRh* Response6.7 (4.5 to NA)
SecondaryPercentage of Participants With Complete Remission (CR) During the First Two Treatment Cycles

Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts. Complete remission was defined as meeting all 3 of the following criteria: * less than or equal to 5% blasts in the bone marrow; * no evidence of disease; * full recovery of peripheral blood counts: platelets \> 100,000/μl, and absolute neutrophil count (ANC) \> 1000/μl. Participants without a post-baseline disease assessment were considered non-responders.

Time frame:
Approximately 12 weeks, as of the data cut-off date of 20 May 2015
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission (CR) During the First Two Treatment Cycles
percentage of participantsBlinatumomab
Percentage of Participants With Complete Remission (CR) During the First Two Treatment Cycles31.1 (18.2 to 46.6)
SecondaryPercentage of Participants With Complete Remission With Partial Hematological Recovery (CRh*) During the First Two Treatment Cycles

Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts. Complete remission with partial hematological recovery (CRh\*) was defined as meeting all 3 of the following criteria: * less than or equal to 5% blasts in the bone marrow; * no evidence of disease; * partial recovery of peripheral blood counts: platelets \> 50,000/μl, and ANC \> 500/μl. Participants without a post-baseline disease assessment were considered non-responders.

Time frame:
Approximately 12 weeks, as of the data cut-off date of 20 May 2015
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission With Partial Hematological Recovery (CRh*) During the First Two Treatment Cycles
percentage of participantsBlinatumomab
Percentage of Participants With Complete Remission With Partial Hematological Recovery (CRh*) During the First Two Treatment Cycles4.4 (0.5 to 15.1)
SecondaryPercentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi) During the First Two Treatment Cycles

Efficacy was evaluated via a central bone marrow aspiration and local peripheral blood counts. Complete remission was defined as meeting the following criteria: * less than or equal to 5% blasts in the bone marrow; * no evidence of disease; * full recovery of peripheral blood counts: platelets \> 100,000/μl, and absolute neutrophil count (ANC) \> 1000/μl. Complete remission with partial hematological recovery was defined as meeting the following criteria: * less than or equal to 5% blasts in the bone marrow; * no evidence of disease; * partial recovery of peripheral blood counts: platelets \> 50,000/μl, and ANC \> 500/μl. Complete remission with incomplete hematologic recovery was defined as meeting all of the following criteria: * less than or equal to 5% blasts in the bone marrow; * no evidence of disease; * incomplete recovery of peripheral blood counts: platelets \> 100,000/μl or ANC \> 1000/μl. Participants without a post-baseline disease assessment were considered non-responders.

Time frame:
Approximately 12 weeks, as of the data cut-off date of 20 May 2015
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi) During the First Two Treatment Cycles
percentage of participantsBlinatumomab
Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi) During the First Two Treatment Cycles40.0 (25.7 to 55.7)
SecondaryOverall Survival

Overall survival was assessed from the date the participant received the first infusion of blinatumomab until death from any cause or the date of the last follow-up. Participants still alive at the data cut-off date were censored on the last documented visit date or the date of the last contact when the patient was last known to have been alive.

Time frame:
From first dose of blinatumomab until the data cut-off date; median observation time was 8.8 months.
Reported as:
Median · months
Overall Survival
monthsBlinatumomab
Overall Survival7.1 (5.6 to NA)
SecondaryPercentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission

Participants who achieved remission (CR/CRh\*) during the first 2 cycles of treatment and received an allogeneic HSCT.

Time frame:
Up to the data cut-of date of 20 May 2015; Maximum duration on study was 14.5 months.
Reported as:
Number · percentage of participants
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission
percentage of participantsBlinatumomab
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission43.8 (19.8 to 70.1)
Secondary100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant

The analysis of 100-day mortality after allogeneic HSCT was assessed for participants who received an allogeneic HSCT while in remission (CR/CRh\*) after 2 cycles of blinatumomab treatment and did not receive any additional antileukemic treatment. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT. The 100-day mortality rate after allogeneic HSCT was defined as the percentage of participants having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive.

Time frame:
From the date of allogeneic HSCT until the data cut-off date of 20 May 2015; median observation time was 3.2 months.
Reported as:
Number · percentage of participants
100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant
percentage of participantsBlinatumomab
100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant25.0 (3.9 to 87.2)
SecondaryNumber of Participants With Adverse Events

Adverse events (AEs) were graded for severity according to the CTCAE version 4.0, where Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE. Treatment-related adverse events (TRAEs) were those assessed by the investigator as possibly related to blinatumomab based on response to the question: Is there a reasonable possibility that the event may have been caused by blinatumomab or other protocol-specified therapies/procedures?

Time frame:
From the first dose of blinatumomab until 30 days after the last dose, up to the cut-off date of 20 May 2015; the median duration of treatment was 53.8 days.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsBlinatumomab
Any adverse event45
AE grade ≥ 337
AE grade ≥ 418
Serious adverse events28
Leading to discontinuation of blinatumomab3
Leading to interruption of blinatumomab16
Fatal adverse events5
Treatment-related adverse events41
Treatment-related AE grade ≥ 320
Treatment-related AE grade ≥ 47
Treatment-related serious adverse events12
TRAE leading to discontinuation of blinatumomab2
TRAE leading to interruption of blinatumomab12
Treatment-related fatal adverse events1
SecondaryNumber of Participants Who Developed Anti-blinatumomab Antibodies

Anti-blinatumomab binding antibodies were evaluated with a validated blinatumomab anti-drug antibody assay with the electrochemiluminescence detection technology.

Time frame:
Day 29 of each treatment period and 30 days after the last dose
Reported as:
Number · participants
Number of Participants Who Developed Anti-blinatumomab Antibodies
participantsBlinatumomab
Number of Participants Who Developed Anti-blinatumomab Antibodies0
SecondarySteady State Concentration of Blinatumomab
Time frame:
Cycle 1, day 8, 6 to 8 hours after the dose step to 28 μg/day, and Cycle 2, day 1, 6 to 8 hours after blinatumomab infusion
Reported as:
Geometric mean · pg/mL
Steady State Concentration of Blinatumomab
pg/mLBlinatumomab
Cycle 1449 ± 125.6
Cycle 2 (n = 21)532 ± 128.7

Adverse events

Collected over From the first dose of blinatumomab until 30 days after the last dose, up to the cut-off date of 20 May 2015; the median duration of treatment was 53.8 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinatumomab—28/45 (62.2%)45/45 (100%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventBlinatumomab
Febrile neutropeniaBlood and lymphatic system disorders4/45
Device related infectionInfections and infestations3/45
SepsisInfections and infestations3/45
TremorNervous system disorders3/45
LeukocytosisBlood and lymphatic system disorders2/45
Non-cardiac chest painGeneral disorders2/45
PyrexiaGeneral disorders2/45
Respiratory failureRespiratory, thoracic and mediastinal disorders2/45
AnaemiaBlood and lymphatic system disorders1/45
Lymph node painBlood and lymphatic system disorders1/45
Most frequent other events
Showing 10 of 51
Most frequent other events
EventBlinatumomab
PyrexiaGeneral disorders26/45
Febrile neutropeniaBlood and lymphatic system disorders15/45
HeadacheNervous system disorders14/45
AnaemiaBlood and lymphatic system disorders12/45
ThrombocytopeniaBlood and lymphatic system disorders10/45
DiarrhoeaGastrointestinal disorders9/45
Oedema peripheralGeneral disorders8/45
HypokalaemiaMetabolism and nutrition disorders8/45
Bone painMusculoskeletal and connective tissue disorders8/45
ConstipationGastrointestinal disorders7/45

Baseline characteristics

Age, Continuous
Age, Continuous(years)Blinatumomab
Mean52.8 ± 15.0
Age, Customized
Age, Customized(participants)Blinatumomab
18 to < 35 years5
35 to < 55 years17
55 to < 65 years11
≥ 65 years12
Sex: Female, Male
Sex: Female, Male(Participants)Blinatumomab
Female21
Male24
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Blinatumomab
White39
Asian1
Black (or African American)3
Other2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Blinatumomab
Hispanic/Latino2
Not Hispanic/Latino43
Prior Tyrosine Kinase Inhibitor (TKI) Treatment
Prior Tyrosine Kinase Inhibitor (TKI) Treatment(participants)Blinatumomab
1 TKI7
2 TKIs21
3 TKIs13
4 TKIs4
Number of Prior Relapses
Number of Prior Relapses(participants)Blinatumomab
No relapses3
1 relapse25
2 relapses13
≥ 3 relapses4
Number of Prior Salvage Regimens
Number of Prior Salvage Regimens(participants)Blinatumomab
0 regimens14
1 regimen12
2 regimens11
≥ 3 regimens8

2 further baseline measures are reported on the registry.

09

Study locations

22 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    La Jolla, California 92093-0960, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Nantes Cedex 1, 44093, France
  • Research Site
    Paris Cedex 10, 75475, France
  • Research Site
    Toulouse cedex 9, 31059, France
  • Research Site
    Berlin, 12200, Germany
  • Research Site
    Essen, 45122, Germany
  • Research Site
    Frankfurt am Main, 60590, Germany
  • Research Site
    Würzburg, 97080, Germany
  • Research Site
    Bergamo, 24127, Italy
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Venezia, 30174, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    London, NW3 2PF, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
10

References and documents

Publications

  • Martinelli G, Boissel N, Chevallier P, Ottmann O, Gokbuget N, Topp MS, Fielding AK, Rambaldi A, Ritchie EK, Papayannidis C, Sterling LR, Benjamin J, Stein A. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. J Clin Oncol. 2017 Jun 1;35(16):1795-1802. doi: 10.1200/JCO.2016.69.3531. Epub 2017 Mar 29. Erratum In: J Clin Oncol. 2017 Aug 10;35(23):2722. doi: 10.1200/JCO.2017.74.7550. J Clin Oncol. 2017 Aug 20;35(24):2856. doi: 10.1200/JCO.2017.75.0489. PubMed 28355115 ↗
  • Kuchimanchi M, Zhu M, Clements JD, Doshi S. Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy. Br J Clin Pharmacol. 2019 Apr;85(4):807-817. doi: 10.1111/bcp.13864. Epub 2019 Feb 18. PubMed 30645768 ↗
  • Kantarjian HM, Zugmaier G, Bruggemann M, Wood BL, Horst HA, Zeng Y, Martinelli G. Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Cancers (Basel). 2021 Nov 9;13(22):5607. doi: 10.3390/cancers13225607. PubMed 34830762 ↗
  • Clements JD, Zhu M, Kuchimanchi M, Terminello B, Doshi S. Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies. Clin Pharmacokinet. 2020 Apr;59(4):463-474. doi: 10.1007/s40262-019-00823-8. PubMed 31679130 ↗
  • Martinelli G, Boissel N, Chevallier P, Ottmann O, Gokbuget N, Rambaldi A, Ritchie EK, Papayannidis C, Tuglus CA, Morris JD, Stein A. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. Eur J Cancer. 2021 Mar;146:107-114. doi: 10.1016/j.ejca.2020.12.022. Epub 2021 Feb 13. PubMed 33588145 ↗
  • Topp MS, Stein AS, Gokbuget N, Horst HA, Boissel N, Martinelli G, Kantarjian H, Bruggemann M, Chen Y, Zugmaier G. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis. Cancer Med. 2021 Apr;10(8):2601-2610. doi: 10.1002/cam4.3731. Epub 2021 Mar 18. PubMed 33734596 ↗
  • Horst HA, Zugmaier G, Martinelli G, Mergen N, Velasco K, Zaman F, Kantarjian H. CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis. Am J Hematol. 2023 Aug;98(8):E222-E225. doi: 10.1002/ajh.26988. Epub 2023 Jun 22. No abstract available. PubMed 37345570 ↗
  • Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704. PubMed 35622074 ↗

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in May 2015, 16 months.

Results were first posted in Aug 2017, 2 years 2 months after primary completion. A results delay was requested in Dec 2015.

Of 227 phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2013
First posted
Dec 4, 2013
StartActual
Jan 3, 2014
Primary completionActual
May 20, 2015
CompletionActual
Jan 6, 2017
Results delay requested
Dec 22, 2015
Results first posted
Aug 9, 2017
Last update
May 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02000427
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 4, 2013
Start date
Jan 3, 2014
Primary completion
May 20, 2015
Completion
Jan 6, 2017
Results posted
Aug 9, 2017
Last update
May 28, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion